-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Speaker 1

Program: Spotlight Sessions
Session: Emicizumab’s Impact on the Landscape of Hemophilia A Treatment: Two Artists Debate the View
Hematology Disease Topics & Pathways:
Hemophilia, Biological, antibodies, Diseases, Bleeding and Clotting, Therapies, Adverse Events, Clinically relevant
Saturday, December 5, 2020, 11:55 AM-12:00 PM

Guy Young, MD

Cancer and Blood Disorders Institute, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA

Disclosures: Young: Genentech/Roche, Grifols, and Takeda: Research Funding; Bayer, CSL Behring, Freeline, UniQure: Consultancy; BioMarin, Freeline, Genentech/Roche, Grifols, Kedrion, Novo Nordisk, Sanofi Genzyme, Spark, Takeda, and UniQure: Honoraria.

Previous Presentation | Next Presentation >>